TF and breast carcinoma: In this study, we used EMSA with nuclear extracts of human cell lines of different origins (HepG2, hepatocarcinoma; MCF7, breast cancer; and Caco-2, colorectal adenocarcinoma) to demonstrate that the T → A rs2072580 substitution destroyed the binding site of a certain (putatively ubiquitous) TF (Figure 1 and Figure 2).